Goldberg Law PC announces an investigation of claims against Sage Therapeutics, Inc. and advises investors with losses in excess of $50,000 to contact the firm.
Goldberg Law PC announces that it is investigating claims of potential misrepresentations by Sage Therapeutics, Inc. The investigation focuses on whether the company and its officers violated securities laws by issuing misleading information to investors.
The investigation concerns whether the company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on a March 23, 2016, report by Kerrisdale Capital claiming that the company’s main drug, “is little more than a Band-Aid, achieving, at best, a temporary reduction in brain activity—very similar to many other treatments that doctors already use.”
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
